FDA Greenlights Generics for Flu Drug FLUMADINE Without Interruptions
Published Date: 4/9/2025
Notice
Summary
The FDA checked and confirmed that FLUMADINE 100 mg tablets weren’t taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules. People who rely on this flu medicine can keep counting on it without any interruptions or extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generic Approvals Can Continue
The FDA determined that FLUMADINE (rimantadine hydrochloride) tablet, 100 milligrams, was not withdrawn from sale for reasons of safety or effectiveness. Because of that determination, the FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this product and will allow ANDAs that refer to the product to continue being approved if they meet legal and regulatory requirements.
Patient Access Preserved
If you rely on FLUMADINE (rimantadine hydrochloride) tablet, 100 milligrams, the FDA confirmed it was not withdrawn for safety or effectiveness. That means FDA will allow generic approvals to continue, so people who use this flu medicine can expect continued availability without interruption as long as manufacturers meet approval rules.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in